Skip to main content
Clinical Trials/NCT00138710
NCT00138710CompletedPhase 3

Short-term Effects of Aromatase Inhibition in Obese Men

Rijnstate Hospital2 sites in 1 country50 target enrollmentStarted: August 1, 2005Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
50
Locations
2
Primary Endpoint
Body weight

Study Overview

Brief Summary

In this study, 50 obese men with a hormonal imbalance will be treated with letrozole or placebo for six months in order to examine the effects on the hormonal balance, and on weight loss. The study will also address the side effects and psychological effects of letrozole as compared to placebo.

Detailed Description

The aim of the study is to establish the short-term efficacy and safety of aromatase inhibition in restoring and maintaining eugonadism in hypogonadotrophic hypogonadal men. Secondary aim is to detect the short-term somatic and psychological effects.

Study design: Double blind randomized placebo-controlled trial.

Treatment: 26 weeks of either letrozole or placebo. All patients will start on 1 tablet per week, dose adjustments will be performed if serum testosterone or estradiol are outside the target range. All men will be prescribed a mildly hypocaloric diet.

Endpoints: BMI, body weight, waist circumference, body composition, exercise capacity, serum levels of several hormone markers, glucose tolerance, psychological characteristics.

All patients will be measured 6 times during the study.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
20 Years to 50 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • BMI between 35 and 50
  • Ages between 20 and 50
  • Serum total testosterone under 10 nmol/l
  • Serum luteinizing hormone (LH) under 9 mU/l
  • Serum estradiol over 40 pmol/l

Exclusion Criteria

  • Comorbidity
  • Serum prostate-specific antigen (PSA) over 4.0 U/l
  • Discontinuation of smoking less than six months ago
  • Medication known to affect hormonal parameters

Outcomes

Primary Outcomes

Body weight

Body mass index (BMI)

Waist circumference

Body composition

Exercise capacity

Serum levels of hormones

Glucose tolerance

Reported side effects

Psychological characteristics (Symptom Checklist, intelligence quotient [IQ] NPV)

Secondary Outcomes

  • Lipid profile
  • Blood counts
  • Bone markers
  • Liver enzymes

Investigators

Sponsor
Rijnstate Hospital
Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials

Short-term Effects of Aromatase Inhibition... | Clinical Trial